Indian Natco marketed Glivec's copy product

An Indian pharmaceutical maker Natco marketed on January 26 Veenat (imatinib mesylate), an identical substance to Glivec through the market approval from the Indian government. Any pharmaceutical makers can produce copy products like Glivec due to the fact that India has not introduced a product patent system.

With the same indications such as chronic myeloid leukemia and gastrointestinal s...